719307-48-9

Upstream product

• 4668-43-3 (S)-3-(benzyloxycarbonylamino)-4-ethoxy-4-oxobutanoic acid 
• 719308-47-1 (2S)-2-amino-3-(5-phenyl-oxazol-2-yl)-propionic acid isobutyl ester hydrochloride 
• 719308-31-3 (2S)-2-amino-3-(5-phenyl-oxazol-2-yl)-propionic acid ethyl ester hydrochloride 
• 719307-95-6 (2S)-2-benzyloxycarbonylamino-N-(2-oxo-2-phenyl-ethyl)-succinamic acid ethyl ester 
• 719308-09-5 (2S)-2-benzyloxycarbonylamino-3-(5-phenyl-oxazol-2-yl)-propionic acid ethyl ester 
• 755753-54-9 (2S)-2-amino-3-(5-phenyl-oxazol-2-yl)-propionic acid ethyl ester 

Downstream Products

• 872221-56-2 potassium-(2S)-2-{1-[(1S)-1-isobutoxycarbonyl-2-(5-phenyl-oxazol-2-yl)-ethylcarbamoyl]-cyclopentylmethyl}4-methoxy-butyrate 

Relevant academic research and scientific papers

NEUTRAL ENDOPEPTIDASE INHIBITOR POLYMORPH

Disclosed are (2S)-2-{1-[(1S)-1-Isobutoxycarbonyl-2-(5-phenyl-oxazol-2-yl)-ethylcarbamoyl]-cyclopentylmethyl}-4-methoxy-butyric, Potassium-(2S)-2-{1-[(1S)-1-Isobutoxycarbonyl-2-(5-phenyl-oxazol-2-yl)-ethylcarbamoyl]-cyclopentylmethyl}-4-methoxy-butyrate,

CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS

The invention relates to NEP inhibitors for treating cardiovascular disorders wherein R1 is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C